Swiss firm plans to acquire Cephalon's ME business

19 October 2011: Swiss-based pharmaceutical firm Acino has signed an agreement with Cephalon Inc. under which Acino is to acquire Cephalon's combined Middle East and African business for a total of around €80m. The business to be acquired includes product portfolio comprising brands such the analgesic Olfen (diclofenac), the anti-spasmotic Spasfon (phloroglucinol/trimethylphloroglucinol), the gastrointestinal drug Gasec (omeprazole) and the antibiotic Mesporin (ceftriaxone).

Source: Ameinfo